Autopsy report · NCT04843579

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients

“low enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 1 year before it stopped.
• 4 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Weill Medical College of Cornell University

Sponsor type

University, hospital or other

Conditions

Myeloma Multiple; Myeloma; Refractory Multiple Myeloma

Interventions

Selinexor; Clarithromycin; Pomalidomide; Dexamethasone

Participants

4

Sites

2

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.